INMB biotech catalysts & pipeline

INMUNE BIO INC · Data as of 2026-09-08

Upcoming catalysts

CORDStrom™ (Ebstrocel™) — NDA/BLA submission

Late - 2026

Late - 2026: CORDStrom BLA (US)*

Source filing

INKmune® — Full data

Q4 2026

Final data analysis is underway, and release is expected in Q4 2026.

Source filing

CORDStrom™ (Ebstrocel™) — NDA/BLA submission

early 2027

We intend to file a Marketing Authorization Application ("MAA") in the United Kingdom by the end of Q3 or early Q4 of 2026 and the European Union in early 2027, followed by a Biologics License Application ("BLA") with the U.S. Food and Drug Administration ("FDA").

Source filing

CORDStrom™ (Ebstrocel™) — NDA/BLA submission

2027

Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.

Source filing

Explore the free biotech catalyst calendar